The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Respiratory Pharmacology
Volume 15 - 2024 |
doi: 10.3389/fphar.2024.1402386
This article is part of the Research Topic Use of Bioactives for Treatment of Respiratory Diseases View all 8 articles
Aspirin reduces the mortality risk of patients with community-acquired pneumonia: A retrospective Propensity-Matched analysis of the MIMIC-IV database
Provisionally accepted- 1 Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China
- 2 Department of Respiratory and Critical Care Medicine, Shanxi Provincial People’s Hospital, xian, China
- 3 Department of Neurology, Fujian Medical University Affiliated Xiamen Hong ′ai Hospital, xiamen, China
Background: Community-acquired pneumonia (CAP) is a common infectious disease characterized by inflammation of the lung parenchyma in individuals who have not recently been hospitalized. It remains a significant cause of morbidity and mortality worldwide. Aspirin is a widely used drug, often administered to CAP patients.However, the benefits of aspirin remain controversial.Objective: We sought to determine whether aspirin treatment has a protective effect on the outcomes of CAP patients.: We selected patients with CAP from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Propensity score matching (PSM) balanced baseline differences. A multivariate Cox regression model assessed the relationship between aspirin treatment and 28-day mortality.Results: A total of 3,595 patients were included, with 2,261 receiving aspirin and 1,334 not. After PSM, 1,219 pairs were matched. The 28-day mortality rate for aspirin users was 20.46%, lower than non-users. Multivariate Cox regression indicated aspirin use was associated with decreased 28-day mortality (HR 0.75, 95% CI 0.63-0.88, p < 0.001). No significant differences were found between 325 mg/day and 81 mg/day aspirin treatments in terms of 28-day mortality, hospital mortality, 90-day mortality, gastrointestinal hemorrhage, and thrombocytopenia. However, intensive care unit (ICU) stay was longer for the 325 mg/day group compared to the 81 mg/day group (4.22 vs. 3.57 days, p = 0.031).Aspirin is associated with reduced 28-day mortality in CAP patients.However, 325 mg/day aspirin does not provide extra benefits over 81 mg/day and may lead to longer ICU stays.
Keywords: Community-acquired pneumonia, Intensive Care Unit, Aspirin, MIMIC-IV database, Mortality
Received: 17 Mar 2024; Accepted: 02 Sep 2024.
Copyright: © 2024 Wang, Sun, Zhang, Wang, Tingting, Ji, Lv, Yu, Cheng, Li, Hu and SHI. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jiaolin Sun, Department of Respiratory and Critical Care Medicine, Shanxi Provincial People’s Hospital, xian, China
Yaxin Zhang, Department of Neurology, Fujian Medical University Affiliated Xiamen Hong ′ai Hospital, xiamen, China
Na Wang, Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China
Lin Lv, Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China
Mengchong Li, Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China
Tinghua Hu, Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China
ZHIHONG SHI, Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.